Along with helping to control blood sugar and boost weight loss, GLP-1s and SGLT-2 inhibitors seem to have other major benefits
(8) Malinda KM, Sidhu GS, Banaudha KK, Gaddipati JP, et al
Altered GLP-1 function has been observed in type 2 diabetes, obesity, and metabolic syndrome, though there is no routine clinical test to measure GLP-1 activity in standard NHS practice
Oral administration Oral peptides face significant bioavailability challenges
First-time prescribing of ADMs decreased slightly in March 2025 relative to December (-6.56%), while first-time prescribing of AOMs increased from December 2024 to January 2025, before remaining relatively stable until March 2025 (+18.63%)